Connor, Clark & Lunn Investment Management (CC&L)’s Anika Therapeutics ANIK Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$330K	Sell	22,736 -37,145	-62%	-$431K	﹤0.01%	1400
2025 Q4	$575K	Buy	59,881 +13,943	+30%	+$134K	﹤0.01%	1271
2025 Q3	$432K	Buy	45,938 +2,944	+7%	+$28.1K	﹤0.01%	1288
2025 Q2	$455K	Buy	42,994 +8,573	+25%	+$108K	﹤0.01%	1282
2025 Q1	$517K	Sell	34,421 -6,984	-17%	-$116K	﹤0.01%	1136
2024 Q4	$682K	Sell	41,405 -16,201	-28%	-$320K	﹤0.01%	1060
2024 Q3	$1.42M	Sell	57,606 -1,212	-2%	-$31.4K	0.01%	766
2024 Q2	$1.49M	Sell	58,818 -1,266	-2%	-$32.8K	0.01%	742
2024 Q1	$1.53M	Buy	60,084 +7,442	+14%	+$180K	0.01%	750
2023 Q4	$1.19M	Buy	52,642 +512	+1%	+$10.6K	0.01%	811
2023 Q3	$971K	Buy	52,130 +5,505	+12%	+$114K	0.01%	831
2023 Q2	$1.21M	Buy	46,625 +30,627	+191%	+$820K	0.01%	743
2023 Q1	$459K	Buy	+15,998	New	+$476K	﹤0.01%	910
2016 Q1	–	Sell	-7,500	Closed	-$286K	–	827
2015 Q4	$286K	Buy	+7,500	New	+$287K	﹤0.01%	638
2015 Q1	–	Sell	-8,800	Closed	-$359K	–	566
2014 Q4	$359K	Sell	8,800 -17,900	-67%	-$700K	﹤0.01%	437
2014 Q3	$979K	Sell	26,700 -3,800	-12%	-$164K	0.01%	309
2014 Q2	$1.5M	Sell	30,500 -14,600	-32%	-$649K	0.01%	276
2014 Q1	$2.05M	Buy	45,100 +15,900	+54%	+$591K	0.02%	272
2013 Q4	$1.18M	Buy	+29,200	New	+$901K	0.01%	339